Ritu Gupta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/174262/publications.pdf

Version: 2024-02-01

394286 1,391 146 19 citations h-index papers

28 g-index 151 151 151 1885 docs citations times ranked citing authors all docs

501076

#	Article	IF	CITATIONS
1	Safety and Efficacy of Bendamustine and Rituximab (BR) Regimen in Indian Chronic Lymphocytic Leukaemia Patients. Indian Journal of Hematology and Blood Transfusion, 2023, 39, 33-39.	0.3	1
2	Autophagy in acute myeloid leukemia: a paradoxical role in chemoresistance. Clinical and Translational Oncology, 2022, 24, 1459-1469.	1.2	6
3	Flow cytometric immunophenotyping of plasma cells across the spectrum of plasma cell proliferative disorders: A fresh insight with patternâ€based recognition. Cytometry Part B - Clinical Cytometry, 2022, 102, 292-302.	0.7	6
4	Leukemic stem cell signatures in Acute myeloid leukemia- targeting the Guardians with novel approaches. Stem Cell Reviews and Reports, 2022, 18, 1756-1773.	1.7	7
5	Relevance of polyclonal plasma cells and postâ€therapy immunomodulation in measurable residual disease assessment in multiple myeloma. Cytometry Part B - Clinical Cytometry, 2022, 102, 209-219.	0.7	8
6	ARCANE-ROG: Algorithm for reconstruction of cancer evolution from single-cell data using robust graph learning. Journal of Biomedical Informatics, 2022, 129, 104055.	2.5	4
7	C-NMC: B-lineage acute lymphoblastic leukaemia: A blood cancer dataset. Medical Engineering and Physics, 2022, 103, 103793.	0.8	8
8	Multiple Myeloma: Impact of Time to Transplant on the Outcome. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e826-e835.	0.2	4
9	Long-Term Outcomes and Safety Trends of Autologous Stem-Cell Transplantation in Non-Hodgkin Lymphoma: A Report From A Tertiary Care Center in India. JCO Global Oncology, 2022, 8, e2100383.	0.8	1
10	Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial. British Journal of Haematology, 2022, 198, 288-297.	1.2	5
11	Effect of the sequence of pull of bone marrow aspirates on plasma cell quantification in plasma cell proliferative disorders. International Journal of Laboratory Hematology, 2022, 44, 837-845.	0.7	4
12	Correlation of changes in subclonal architecture with progression in the MMRF CoMMpass study. Translational Oncology, 2022, 23, 101472.	1.7	2
13	Allogeneic hematopoietic stem cell transplant in pediatric acute myeloid leukemia: Lessons learnt from a tertiary care center in India. Pediatric Transplantation, 2021, 25, e13918.	0.5	6
14	Multiple Myelomaâ€"Effect of Induction Therapy on Transplant Outcomes. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 80-90.e5.	0.2	10
15	Ibrutinib-Induced Skin Rash. Turkish Journal of Haematology, 2021, 38, 81-83.	0.2	2
16	Retrospective analysis of a novel molecular genetic risk score, "MRplusâ€; in BCR-ABL1 negative pediatric B-ALL: A single-center experience Journal of Clinical Oncology, 2021, 39, 7029-7029.	0.8	1
17	Stance of MRD in Non-Hodgkin's Lymphoma and its upsurge in the novel era of cell-free DNA. Clinical and Translational Oncology, 2021, 23, 2206-2219.	1.2	2
18	Genome-wide identification of potential biomarkers in multiple myeloma using meta-analysis of mRNA and miRNA expression data. Scientific Reports, 2021, 11, 10957.	1.6	13

#	Article	IF	CITATIONS
19	Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in B-ALL. Annals of Hematology, 2021, 100, 2487-2500.	0.8	6
20	A CNN-based unified framework utilizing projection loss in unison with label noise handling for multiple Myeloma cancer diagnosis. Medical Image Analysis, 2021, 72, 102099.	7.0	20
21	Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial. Journal of Infection and Chemotherapy, 2021, 27, 1743-1749.	0.8	40
22	Al-supported modified risk staging for multiple myeloma cancer useful in real-world scenario. Translational Oncology, 2021, 14, 101157.	1.7	10
23	Proposal and clinical application of molecular genetic risk scoring system, "MRplusâ€, for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre. Leukemia Research, 2021, 111, 106683.	0.4	5
24	Robust and sustained antibody response to SARSâ€CoVâ€2 in a child pre and post autologous hematopoietic stem cell transplant. Pediatric Blood and Cancer, 2021, 68, e28848.	0.8	2
25	Does Ethnicity Matter in Multiple Myeloma Risk Prediction in the Era of Genomics and Novel Agents? Evidence From Real-World Data. Frontiers in Oncology, 2021, 11, 720932.	1.3	5
26	Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India. Frontiers in Oncology, 2021, 11, 770747.	1.3	3
27	Cytokine profile in multiple myeloma. Cytokine, 2020, 136, 155271.	1.4	29
28	GCTI-SN: Geometry-inspired chemical and tissue invariant stain normalization of microscopic medical images. Medical Image Analysis, 2020, 65, 101788.	7.0	43
29	Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 902.	0.7	16
30	Molecular signature comprising 11 platelet-genes enables accurate blood-based diagnosis of NSCLC. BMC Genomics, 2020, 21, 744.	1.2	13
31	A Real-world Perspective of CD123 Expression in Acute Leukemia as Promising Biomarker to Predict Treatment Outcome in B-ALL and AML. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e673-e684.	0.2	14
32	SDCT-AuxNet: DCT augmented stain deconvolutional CNN with auxiliary classifier for cancer diagnosis. Medical Image Analysis, 2020, 61, 101661.	7.0	43
33	RNA-Seq profiling of deregulated miRs in CLL and their impact on clinical outcome. Blood Cancer Journal, 2020, 10, 6.	2.8	20
34	Imputation of Gene Expression Data in Blood Cancer and Its Significance in Inferring Biological Pathways. Frontiers in Oncology, 2020, 9, 1442.	1.3	13
35	Real-world Experience of Imatinib in Pediatric Chronic Phase Chronic Myeloid Leukemia: A Single-center Experience From India. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e437-e444.	0.2	6
36	Real-Time Molecular Monitoring in Acute Myeloid Leukemia With Circulating Tumor DNA. Frontiers in Cell and Developmental Biology, 2020, 8, 604391.	1.8	10

#	Article	IF	CITATIONS
37	Clinico-demographic profile & Description of COVID-19 patients admitted at a tertiary care centre in north India. Indian Journal of Medical Research, 2020, 152, 61.	0.4	72
38	Glucose Regulated Protein (GRP78) as a Biomarker of Response to Bortezomibâ€based Regimen in Multiple Myeloma. FASEB Journal, 2020, 34, 1-1.	0.2	0
39	EDNFC-Net: Convolutional Neural Network with Nested Feature Concatenation for Nuclei-Instance Segmentation., 2020,,.		10
40	Non-Hodgkin lymphoma: The Indian scene Journal of Clinical Oncology, 2020, 38, e20063-e20063.	0.8	0
41	B-Acute Lymphoblastic Leukemia in a Follow-up Case of Breast Cancer. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 99-101.	0.1	0
42	Levels of expression of CD45 for normal lymphocytes in different leukemic cases by flowcytometry. Indian Journal of Pathology and Microbiology, 2020, 63, 505.	0.1	0
43	Better Therapeutic Target to Enhance Cisplatin Sensitivity in Cervical Cancer: PARP-1 or \hat{l}^2 -catenin. Journal of Cancer Science and Clinical Therapeutics, 2020, 04, .	0.2	1
44	Regulatory T cells in pediatric AML are associated with disease load and their serial assessment suggests role in leukemogenesis. American Journal of Blood Research, 2020, 10, 90-96.	0.6	4
45	Chronic Lymphocytic Leukemia with Dermatomyositis: A Therapeutic Challenge. Turkish Journal of Haematology, 2020, 37, 291-292.	0.2	0
46	Acute Myeloid Leukemia: An Update., 2019,, 163-182.		2
47	CT-NNBI: Method to Impute Gene Expression Data using DCT Based Sparsity and Nuclear Norm Constraint with Split Bregman Iteration. , 2019, , .		2
48	PARP-1 inhibitor modulate \hat{l}^2 -catenin signaling to enhance cisplatin sensitivity in cancer cervix. Oncotarget, 2019, 10, 4262-4275.	0.8	20
49	Rapid Identification of Key Copy Number Alterations in B- and T-Cell Acute Lymphoblastic Leukemia by Digital Multiplex Ligation-Dependent Probe Amplification. Frontiers in Oncology, 2019, 9, 871.	1.3	16
50	CD123 is an Important Predictor of Post Induction Response and Early Treatment Outcome in Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S197.	0.2	0
51	Role of CD123 as Determinant of Minimal Residual Disease in Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S235.	0.2	0
52	Determination of CNVs by NGS Based Digital MLPA in Multiple Myeloma And Their Effect on Clinical Outcome. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e66-e67.	0.2	0
53	Effect of Concomitant Deletions of CDKN2A/B, PAX5 and Pseudoautosomal Region Genes along with IKZF1 Deletions (IKZF1-Plus) on Outcome in BCR-ABL1 Negative Pediatric B-Cell Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S198-S199.	0.2	O
54	Clinical Outcome of Cases with Isolated MLPA Finding of Amplification of Chromosome 21 Genes (AMP21-MLPA) is Similar to Other Cases of BCR-ABL1 Negative Pediatric B-Cell Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S199-S200.	0.2	O

#	Article	IF	CITATIONS
55	Treatment Related Acute Myeloid Leukemia in Breast Cancer Survivors: A Single Institutional Experience. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 561-562.	0.3	O
56	Leukemia Cutis: A Rare Initial Presentation of Chronic Lymphocytic Leukemia. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 367-368.	0.3	2
57	Characteristics and Outcome of Relapsed Myeloma after Single Autologous Stem Cell Transplant: 20-year Experience. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e210-e211.	0.2	0
58	Post-transplant minimal residual disease assessment in Multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e180.	0.2	0
59	Modified risk stratification (MRS) for Multiple Myeloma- A simplified model using machine learning. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e207-e208.	0.2	0
60	Inferring Biological Pathways in Multiple Myeloma after Missing Value Imputation. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e67.	0.2	0
61	VRd versus VCd as induction therapy for newly diagnosed multiple myeloma: A Phase III, randomized study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e361.	0.2	6
62	Clinical impact of chromothriptic complex chromosomal rearrangements in newly diagnosed multiple myeloma. Leukemia Research, 2019, 76, 58-64.	0.4	9
63	Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort. Annals of Hematology, 2019, 98, 437-443.	0.8	9
64	High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome. Indian Journal of Medical Research, 2019, 149, 730.	0.4	23
65	Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma. Clinical Hematology International, 2019, 1, 205-219.	0.7	1
66	Chronic lymphocytic leukemia with deletion 17p: An Indian scenario. South Asian Journal of Cancer, 2019, 08, 40-51.	0.2	2
67	FLI1 and MIC2 expression in precursor B-lymphoblastic leukemia with Burkitt-like morphology and extensive extramedullary involvement: A diagnostic challenge in pediatric small round cell tumor. Indian Journal of Pathology and Microbiology, 2019, 62, 614.	0.1	2
68	Chronic lymphocytic leukemia: An Indian experience Journal of Clinical Oncology, 2019, 37, e19007-e19007.	0.8	2
69	Comparison between photostability of Alexa Fluor 448 and Alexa Fluor 647 with conventional dyes <scp>FITC</scp> and <scp>APC</scp> by flow cytometry. International Journal of Laboratory Hematology, 2018, 40, e52-e54.	0.7	7
70	PCSeg: Color model driven probabilistic multiphase level set based tool for plasma cell segmentation in multiple myeloma. PLoS ONE, 2018, 13, e0207908.	1.1	25
71	Prevalence of Monoclonal Gammopathy of Undetermined Significance in India—A Hospital-based Study. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e345-e350.	0.2	10
72	Nucleic acid based risk assessment and staging for clinical practice in multiple myeloma. Annals of Hematology, 2018, 97, 2447-2454.	0.8	4

#	Article	IF	CITATIONS
73	Clinical and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in Indian patients. Journal of Applied Hematology, 2018, 9, 85.	0.1	2
74	Prospective evaluation of minimal residual disease in multiple myeloma following autologous stem cell transplantation(ASCT) and consolidation therapy Journal of Clinical Oncology, 2018, 36, e20033-e20033.	0.8	0
75	Adult Burkitt lymphoma: An institutional experience with a uniform chemotherapy protocol. South Asian Journal of Cancer, 2018, 07, 195-199.	0.2	2
76	SD-Layer: Stain Deconvolutional Layer for CNNs in Medical Microscopic Imaging. Lecture Notes in Computer Science, 2017, , 435-443.	1.0	51
77	Stain Color Normalization and Segmentation of Plasma Cells in Microscopic Images as a Prelude to Development of Computer Assisted Automated Disease Diagnostic Tool in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e99.	0.2	33
78	Immunophenotyping Patterns of Plasma cells in Plasma Cell Proliferative Disorders. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e99-e100.	0.2	4
79	Bortezomib, Lenalidomide and Low-dose Dexamethasone (VRD) Versus Lenalidomide and Low-dose Dexamethasone (Ld) for Newly-diagnosed Multiple Myeloma- A Randomized Phase III Study-Interim Results. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e5-e6.	0.2	2
80	Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome. Bone Marrow Transplantation, 2017, 52, 1473-1475.	1.3	22
81	Profiling of miRnome in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e3.	0.2	0
82	Influence of Predictor Genes of TC Classification on Clinical Outcome in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e35-e36.	0.2	0
83	Dissecting Genetic Aberrations in Multiple Myeloma Using aCGH and MLPA. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e36.	0.2	0
84	Genome-wide DNA methylation profiling integrated with gene expression profiling identifies PAX9 as a novel prognostic marker in chronic lymphocytic leukemia. Clinical Epigenetics, 2017, 9, 57.	1.8	25
85	Minimal residual disease evaluation in autologous stem cell transplantation recipients with multiple myeloma. Leukemia and Lymphoma, 2017, 58, 1234-1237.	0.6	13
86	Bortezomib, Lenalidomide and Low-Dose Dexamethasone (VRD) Versus Lenalidomide and Low-Dose Dexamethasone (Ld) for Newly-Diagnosed Multiple Myeloma- a Randomized Phase III Study. Blood, 2017, 130, 906-906.	0.6	5
87	Multiâ€drug resistance protein 1 as prognostic biomarker in clinical practice for acute myeloid leukemia. International Journal of Laboratory Hematology, 2016, 38, e93-7.	0.7	5
88	Cumulative therapeutic effects of phytochemicals in <i>Arnica montana</i> flower extract alleviated collagenâ€induced arthritis: inhibition of both proâ€inflammatory mediators and oxidative stress. Journal of the Science of Food and Agriculture, 2016, 96, 1500-1510.	1.7	26
89	Overlapping cell nuclei segmentation in microscopic images using deep belief networks. , 2016, , .		48
90	Vascular endothelial growth factor expression in pediatric non-Hodgkin lymphoma: A prospective study. Pediatric Hematology and Oncology, 2016, 33, 168-170.	0.3	0

#	Article	IF	Citations
91	Prognostic Relevance of T Regulatory Cells in Patients with Advanced-Stage Serous Carcinoma Ovary. Indian Journal of Gynecologic Oncology, 2016, 14, 1.	0.1	O
92	Therapy Related Acute Myeloid Leukemia with t(8;16) Mimicking Acute Promyelocytic Leukemia. Indian Journal of Hematology and Blood Transfusion, 2016, 32, 20-22.	0.3	0
93	Serial assessment of circulating T regulatory cells and T helper 17 cells in pediatric non-Hodgkin lymphoma: a prospective study. Leukemia and Lymphoma, 2016, 57, 1739-1742.	0.6	0
94	Immunoglobulin heavy chain variable region gene repertoire and B-cell receptor stereotypes in Indian patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2016, 57, 2389-2400.	0.6	7
95	Evaluation of serum Cystatin-C as a prognostic and predictive factor in patients with newly diagnosed multiple myeloma Journal of Clinical Oncology, 2016, 34, 8044-8044.	0.8	1
96	High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in FLT3 internal tandem duplication (ITD) negative patients in adult acute myeloid leukaemia: A prospective pilot study from India. Indian Journal of Medical Research, 2016, 143, 11.	0.4	5
97	Dysregulation of nuclear factor-kappaB pathway in multiple myeloma patients at diagnosis and relapse Journal of Clinical Oncology, 2016, 34, 8050-8050.	0.8	0
98	Abstract 2152: PJ34-mediated PARP-1 enzymatic activity inhibition in cervical cancer modulates the cellular response to cisplatin. , 2016, , .		0
99	Autologous stem cell transplantation for multiple myeloma: Long-term results. The National Medical Journal of India, 2016, 29, 192-199.	0.1	18
100	An unusual case of phenotype switch between AML FAB subtypes. Clinical Case Reports (discontinued), 2015, 3, 118-120.	0.2	1
101	Longâ€term outcomes for patients with acute myeloid leukemia: A singleâ€center experience from <scp>AllMS</scp> , <scp>I</scp> ndia. Asia-Pacific Journal of Clinical Oncology, 2015, 11, 242-252.	0.7	23
102	Autologous stem cell Transplantation (ASCT) for Multiple Myeloma (MM): Predictors of long term outcome. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e145-e146.	0.2	0
103	Low dose dexamethasone plus lenalidomide (Len-dexa) versus thalidomide (Thal-dexa) as induction therapy for newly diagnosed multiple myeloma: A Phase III, randomized study. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e146.	0.2	4
104	Serum Cytokine Levels in Patients of Multiple Myeloma at Diagnosis and at Relapse. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e252.	0.2	0
105	Novel Cytogenetic Aberrations in a Patient of Chronic Myeloid Leukemia with Blast Crisis. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, XD05-XD06.	0.8	1
106	Impact of DNA methylation and gene expression profile on treatment initiation and treatment free survival in early stage CLL Journal of Clinical Oncology, 2015, 33, e22073-e22073.	0.8	0
107	Acute Myeloid Leukemia Presenting as "Bowel Upset― A Case Report. Journal of Clinical and Diagnostic Research JCDR, 2014, 8, FD09-10.	0.8	10
108	Synchronous metastatic pulmonary adenocarcinoma with small cell lymphoma. Leukemia and Lymphoma, 2014, 55, 1678-1680.	0.6	0

#	Article	IF	CITATIONS
109	Circulating T-regulatory cells in PNET: A prospective study. Pediatric Blood and Cancer, 2014, 61, 228-232.	0.8	6
110	Circulating T-Regulatory Cells in Neuroblastoma: A Pilot Prospective Study. Pediatric Hematology and Oncology, 2014, 31, 717-722.	0.3	21
111	Prognostic and Predictive Significance of Smudge Cell Percentage on Routine Blood Smear in Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 514-517.	0.2	20
112	Chronic Neutrophilic Leukemia with V617F JAK2 Mutation. Indian Journal of Hematology and Blood Transfusion, 2014, 30, 139-142.	0.3	10
113	Complete response after autologous stem cell transplant in multiple myeloma. Cancer Medicine, 2014, 3, 939-946.	1.3	23
114	Attenuation of collagen induced arthritis by Centella asiatica methanol fraction via modulation of cytokines and oxidative stress. Biomedical and Environmental Sciences, 2014, 27, 926-38.	0.2	13
115	Chronic lymphocytic leukemia with massive ascites: An unusual presenting manifestation. South Asian Journal of Cancer, 2014, 03, 235-236.	0.2	1
116	Synergistic effect of vascular endothelial growth factor and angiopoietin-2 on progression free survival in multiple myeloma. Leukemia Research, 2013, 37, 410-415.	0.4	16
117	Angiopoietins as biomarker of disease activity and response to therapy in multiple myeloma. Leukemia and Lymphoma, 2013, 54, 1473-1478.	0.6	15
118	Solitary plasmacytoma: 10 years' experience at All India Institute of Medical Sciences, New Delhi. Leukemia and Lymphoma, 2013, 54, 1665-1670.	0.6	7
119	Coexistence of scleroderma with multiple myeloma: a rare association. BMJ Case Reports, 2013, 2013, bcr2013200639-bcr2013200639.	0.2	9
120	Priapism as an initial presentation of chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 1638-1639.	0.6	8
121	Assessment of 285 cases of chronic lymphocytic leukemia seen at single large tertiary center in Northern India. Leukemia and Lymphoma, 2012, 53, 1961-1965.	0.6	23
122	Circulating endothelial progenitor cells as potential prognostic biomarker in multiple myeloma. Leukemia and Lymphoma, 2012, 53, 635-640.	0.6	21
123	Plasma Cell Leukemia: Case Series From a Tertiary Center with Review of Literature. Indian Journal of Hematology and Blood Transfusion, 2012, 28, 10-14.	0.3	12
124	Dasatinib in chronic myeloid leukemia: A limited Indian experience. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 375-379.	0.7	2
125	Pediatric Myelodysplastic Syndrome With Cytoplasmic Vacuolation in Myeloid Precursors. Journal of Pediatric Hematology/Oncology, 2011, 33, 59-61.	0.3	4
126	Acute myeloid leukaemia with Pseudoâ€Chediak–Higashi granules and intracytoplasmic vacuoles. European Journal of Haematology, 2011, , no.	1.1	6

#	Article	IF	Citations
127	Diagnostic Dilemma of JMML Coexisting with CMV Infection. Indian Journal of Pediatrics, 2011, 78, 485-487.	0.3	5
128	Reconstitution of regulatory T cells after autologous transplantation in multiple myeloma. International Journal of Hematology, 2011, 94, 578-579.	0.7	6
129	Significantly reduced regulatory T cell population in patients with untreated multiple myeloma. Leukemia Research, 2011, 35, 874-878.	0.4	49
130	Nonleukemic granulocytic sarcoma of kidney with mixed phenotype blasts: A diagnostic dilemma. Indian Journal of Pathology and Microbiology, 2011, 54, 606.	0.1	10
131	Acute basophilic leukemia in an infant with proptosis. Indian Journal of Pathology and Microbiology, 2011, 54, 210.	0.1	0
132	Juvenile Myelomonocytic Leukemia Presenting With Coexistent Cytomegalovirus Infection—A Case Report. Journal of Pediatric Hematology/Oncology, 2010, 32, e153-e154.	0.3	1
133	Childhood Chronic Myeloid Leukemia with Monocytosis. Indian Journal of Pediatrics, 2010, 77, 1143-1145.	0.3	8
134	Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country. Leukemia and Lymphoma, 2010, 51, 1850-1854.	0.6	11
135	Unusual cytochemical reactivity for toluidine blue in granular acute lymphoblastic leukemia: a report of two rare cases. Turkish Journal of Haematology, 2010, 27, 43-5.	0.2	1
136	Flow Cytometric Immunophenotyping and Minimal Residual Disease Analysis in Multiple Myeloma. American Journal of Clinical Pathology, 2009, 132, 728-732.	0.4	55
137	Paroxysmal nocturnal hemoglobinuria clone in a case of myelodysplastic syndrome rapidly progressing to acute leukemia. Indian Journal of Hematology and Blood Transfusion, 2009, 25, 33-35.	0.3	0
138	Transient myeloproliferation mimicking JMML associated with parvovirus infection of infancy. Pediatric Blood and Cancer, 2009, 52, 411-413.	0.8	20
139	Analysis of bone marrow plasma cells in patients with solitary bone plasmacytoma. Cancer Therapy, 2009, 7, 49-52.	2.9	3
140	T-cell prolymphocytic leukemia: a report of two cases with review of literature. Indian Journal of Hematology and Blood Transfusion, 2008, 24, 178-181.	0.3	4
141	Synchronous Presentation of Multiple Myeloma and Lung Cancer. Journal of Clinical Oncology, 2008, 26, 5814-5816.	0.8	10
142	Splenic lymphoma with villous lymphocytes. Indian Journal of Pathology and Microbiology, 2008, 51, 113.	0.1	2
143	Immunophenotypic patterns in precursor T-cell neoplasm. Indian Journal of Pathology and Microbiology, 2007, 50, 75-7.	0.1	0
144	Acute basophilic leukemia: Case report. American Journal of Hematology, 2004, 76, 134-138.	2.0	16

RITU GUPTA

#	Article	lF	CITATIONS
145	Metastatic Anaplastic Oligodendroglioma Simulating Acute Leukemia. Acta Cytologica, 2003, 47, 467-469.	0.7	24
146	A Unified Computational Framework for a Robust, Reliable, and Reproducible Identification of Novel miRNAs From the RNA Sequencing Data. Frontiers in Bioinformatics, 0, 2, .	1.0	0